Argos Therapeutics, Inc. And DC Bio Corp. Announce New Clinical Trial To Begin For Chronic Lymphocytic Leukemia

DURHAM, N.C.--(BUSINESS WIRE)--Nov. 8, 2005--Immunotherapy pioneer Argos Therapeutics in conjunction with Toronto-based DC Bio Corp., announced that a clinical trial for chronic lymphocytic leukemia (CLL) is scheduled to begin in Q1 2006 using Argos’s proprietary RNA-loaded dendritic cell vaccine technology. The investigator-sponsored Phase I/II study will be conducted at McMaster University in Hamilton, Ontario, Canada, by Graeme Fraser, M.D., F.R.C.P.C. McMaster University received a $573,000 grant from the Ontario Cancer Research Network (OCRN) to conduct the clinical trial.

MORE ON THIS TOPIC